On July 29, GE HEALTHCARE TECHNOLOGIES INC rose 5.76% in pre-market trading, trading at $69.5/share, with turnover of $108,000. The move follows the company's Q2 earnings release and reaffirmation of full-year guidance.

The company issued 2026 adjusted EPS guidance of $4.80 to $5.00, in line with the FactSet consensus estimate of $4.88. This reaffirmation carries significance given that in April the company had lowered its full-year outlook from an original $4.95-$5.15 range due to elevated memory chip, oil, and freight costs. Preliminary Q2 results disclosed on July 24 had already signaled strong business momentum, alongside a CFO transition announcement. The earnings pre-release noted that the company expects to offset more than half of inflationary headwinds through pricing actions and cost optimization measures, while global end-market demand remains healthy across its imaging, ultrasound, and patient care segments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)